Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Deutsche Bank Aktiengesellschaft to Buy Rating

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other equities research analysts have also recently commented on the company. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Trading Up 1.1%

Shares of OTCMKTS BAYRY opened at $13.85 on Thursday. Bayer Aktiengesellschaft has a fifty-two week low of $7.19 and a fifty-two week high of $14.85. The firm has a market capitalization of $54.43 billion, a P/E ratio of -21.64, a P/E/G ratio of 4.37 and a beta of 0.54. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70. The company’s 50 day simple moving average is $11.06 and its 200 day simple moving average is $11.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.